These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22113150)

  • 1. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
    Schutte AE; Myburgh A; Olsen MH; Eugen-Olsen J; Schutte R
    Thromb Res; 2012 Aug; 130(2):273-7. PubMed ID: 22113150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular matrix biomarker, fibulin-1 and its association with soluble uPAR in a bi-ethnic South African population: the SAfrEIC study.
    du Plooy CS; Kruger R; Huisman HW; Rasmussen LM; Eugen-Olsen J; Schutte AE
    Heart Lung Circ; 2015 Mar; 24(3):298-305. PubMed ID: 25456503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
    Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
    Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.
    Botha S; Fourie CM; Schutte R; Eugen-Olsen J; Schutte AE
    Hypertens Res; 2015 Jun; 38(6):439-44. PubMed ID: 25740290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study.
    Kruger R; Schutte R; Huisman HW; Hindersson P; Olsen MH; Eugen-Olsen J; Schutte AE
    PLoS One; 2013; 8(3):e58506. PubMed ID: 23516493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase plasminogen activator receptor (suPAR) is associated with metabolic changes in HIV-1-infected Africans: a prospective study.
    Fourie CM; Van Rooyen JM; Kruger A; Olsen MH; Eugen-Olsen J; Schutte R; Schutte AE
    Inflammation; 2012 Feb; 35(1):221-9. PubMed ID: 21384094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of suPAR with lifestyle and cardiometabolic risk factors.
    Botha S; Fourie CM; Schutte R; Kruger A; Schutte AE
    Eur J Clin Invest; 2014 Jul; 44(7):619-26. PubMed ID: 24810168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
    Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
    J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
    Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
    J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NT-proBNP is associated with fibulin-1 in Africans: the SAfrEIC study.
    Kruger R; Schutte R; Huisman HW; Argraves WS; Rasmussen LM; Olsen MH; Schutte AE
    Atherosclerosis; 2012 May; 222(1):216-21. PubMed ID: 22349089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.